Unipharma Co (ROCO:6621) Beneish M-Score: -2.85 (As of Jun. 30, 2026)


ROCO:6621 Unipharma Co Ltd ROCO:6621
75 GF Score
Price NT$11.30
GF Value NT$11.67
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Unipharma Co Beneish M-Score?

Unipharma Co ROCO:6621 +0.89% 75 Beneish M-Score is -2.85 as of Jun. 30, 2026. GuruFocus rates ROCO:6621 with a GF Score™ of 75/100 and a GF Value™ of NT$11.67 (Fairly Valued). The stock has 2 warning signs investors should review. Among 908 Drug Manufacturers companies, Unipharma Co ranks better than 78.41% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.85 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Unipharma Co's Beneish M-Score or its related term are showing as below:

ROCO:6621' s Beneish M-Score Range Over the Past 10 Years
Min: -3.83   Med: -2.88   Max: -1.49
Current: -2.85

During the past 13 years, the highest Beneish M-Score of Unipharma Co was -1.49. The lowest was -3.83. And the median was -2.88.


Unipharma Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Unipharma Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unipharma Co Beneish M-Score Chart

Unipharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.83 -1.49 -3.18 -2.92 -2.85

Unipharma Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.18 0.00 -2.92 0.00 -2.85

ROCO:6621 vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Unipharma Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Unipharma Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Unipharma Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Unipharma Co's Beneish M-Score falls into.


ROCO:6621
75GF Score
Unipharma Co Ltd ROCO:6621
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Unipharma Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Unipharma Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9382+0.528 * 0.9762+0.404 * 0.8185+0.892 * 0.9464+0.115 * 0.8299
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1498+4.679 * -0.014073-0.327 * 1.2228
=-2.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$14.97 Mil.
Revenue was NT$88.44 Mil.
Gross Profit was NT$47.22 Mil.
Total Current Assets was NT$184.47 Mil.
Total Assets was NT$274.99 Mil.
Property, Plant and Equipment(Net PPE) was NT$18.56 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$7.00 Mil.
Selling, General, & Admin. Expense(SGA) was NT$68.52 Mil.
Total Current Liabilities was NT$37.94 Mil.
Long-Term Debt & Capital Lease Obligation was NT$7.27 Mil.
Net Income was NT$-40.54 Mil.
Gross Profit was NT$0.00 Mil.
Cash Flow from Operations was NT$-36.67 Mil.
Total Receivables was NT$16.86 Mil.
Revenue was NT$93.46 Mil.
Gross Profit was NT$48.71 Mil.
Total Current Assets was NT$200.01 Mil.
Total Assets was NT$328.98 Mil.
Property, Plant and Equipment(Net PPE) was NT$23.79 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$7.00 Mil.
Selling, General, & Admin. Expense(SGA) was NT$62.96 Mil.
Total Current Liabilities was NT$33.15 Mil.
Long-Term Debt & Capital Lease Obligation was NT$11.07 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(14.967 / 88.444) / (16.856 / 93.455)
=0.169226 / 0.180365
=0.9382

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(48.708 / 93.455) / (47.221 / 88.444)
=0.521192 / 0.533908
=0.9762

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (184.474 + 18.557) / 274.994) / (1 - (200.013 + 23.786) / 328.976)
=0.261689 / 0.31971
=0.8185

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=88.444 / 93.455
=0.9464

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(6.996 / (6.996 + 23.786)) / (6.999 / (6.999 + 18.557))
=0.227276 / 0.273869
=0.8299

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(68.516 / 88.444) / (62.963 / 93.455)
=0.774682 / 0.673725
=1.1498

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((7.265 + 37.937) / 274.994) / ((11.072 + 33.152) / 328.976)
=0.164374 / 0.134429
=1.2228

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-40.544 - 0 - -36.674) / 274.994
=-0.014073

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Unipharma Co has a M-score of -2.85 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.85 mean?
Unipharma Co (ROCO:6621) has a Beneish M-Score of -2.85 as of Jun. 30, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Unipharma Co and its competitors. According to the industry distribution chart, Unipharma Co ranks #196 out of 908 companies in the Drug Manufacturers industry, placing it in the top 21.6%.
Is Unipharma Co's Beneish M-Score too high?
Unipharma Co's current Beneish M-Score is -2.85. Based on the distribution chart, Unipharma Co ranks #196 out of 908 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Unipharma Co has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Unipharma Co's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Unipharma Co ranks #196 out of 908 companies for Beneish M-Score. This places Unipharma Co in the top 22% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Unipharma Co and its competitors. Unipharma Co's current Beneish M-Score is -2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unipharma Co stock overvalued right now?
Based on GuruFocus' analysis, Unipharma Co (ROCO:6621) is currently considered Fairly Valued. The stock's GF Value™ is NT$11.67, compared to a current price of NT$11.30 — trading 3.2% below its estimated fair value. The current Beneish M-Score is -2.85. Unipharma Co's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Unipharma Co (ROCO:6621), the current Beneish M-Score is -2.85 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Unipharma Co (ROCO:6621) Overvalued in 2026?

Based on GuruFocus' analysis, Unipharma Co stock appears to be undervalued. The current stock price of NT$11.30 is trading 3.2% below its estimated GF Value™ of NT$11.67. GuruFocus considers Unipharma Co to be Fairly Valued.

Key valuation signals for ROCO:6621:

  • Beneish M-Score: -2.85
  • GF Value™: NT$11.67 vs. price of NT$11.30 (3.2% below fair value)
  • GF Score™: 75/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6621 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Unipharma Co Business Description

Address Jiu Zong Road, 3rd Floor, No. 17, Lane 171, Section 2, NeiHu District, Taipei, TWN, 11494
Unipharma Co Ltd is a medical diagnostic, pharmaceutical and medical device company. It is engaged in developing drug products and medical equipment. The company's products offerings include Baxter, Tambocor tablets, Bain Injection, Esmolol HCL Injection, Naloxone Injection, and SAM Pelvic Sling medical device. Its customers are major medical centers, regional hospitals, regional hospitals, and clinics.
75GF Score

Get the complete analysis for ROCO:6621

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$11.30
Price
NT$11.67
GF Value